UHPLC Analysis of Aripiprazole and Its Primary Metabolite Dehydro Aripiprazole on Ascentis® Express C18
材料
used together
产品编号
说明
价格
相关产品
产品编号
说明
价格
脱氢阿立哌唑 溶液
1.0 mg/mL in methanol with 5% 1 M HCl, ampule of 1 mL, certified reference material, Cerilliant®阿立哌唑 溶液
1.0 mg/mL (50:50 Methanol/Water with 1% 1N HCl), ampule of 1 mL, certified reference material, Cerilliant®CONDITIONS
column
Ascentis Express C18, 10 cm x 3.0 mm, 2.0 μm particles (50819-U)
mobile phase
[A] 10 mM ammonium formate in water, pH adjusted to 3.0 with formic acid [B] 0.1% formic acid in methanol
gradient
40% B for 0.5 min; to 95% B over 3.5 min; held at 95% B for 2 min
flow rate
0.5 mL/min
pressure
6500 psi (445 bar)
column temp.
35 °C
detector
UV, 245 nm
injection
2 μL
sample
50 μg/mL each compound in 10% methanol
说明
分析说明
Aripiprazole is marketed as the atypical antipsychotic Abilify for the treatment of schizophrenia, bipolar disorder, and clinical depression. Shown here is the UHPLC separation of aripiprazole and a metabolite on a Fused-Core Ascentis Express C18 column. Cerilliant CRMs provided reliable quantification.
法律信息
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany